Use of Risperidone Long-Acting Injection to Support Treatment Adherence and Mood Stabilization in Pediatric Bipolar Patients

2009 ◽  
Vol 70 (4) ◽  
pp. 604-606 ◽  
Author(s):  
Lee Fu-I ◽  
Miguel A. Boarati ◽  
Andreas Stravogiannis ◽  
Yuan-Pang Wang
Keyword(s):  
Treatment Adherence ◽  
Mood Stabilization ◽  
Long Acting ◽  
Bipolar Patients ◽  
Support Treatment

Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: Results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)

2009 ◽  
Vol 24 (5) ◽  
pp. 287-296 ◽  
Author(s):  
J.M. Olivares ◽  
A. Rodriguez-Morales ◽  
J. Diels ◽  
M. Povey ◽  
A. Jacobs ◽  
...  
Keyword(s):  
Observational Study ◽  
Treatment Adherence ◽  
Prospective Observational Study ◽  
Clinical Symptoms ◽  
Retrospective Chart Review ◽  
Treatment Retention ◽  
Severity Scores ◽  
Long Term Treatment ◽  
Long Acting

AbstractBackgroundThe electronic Schizophrenia Treatment Adherence Registry (e-STAR) is a prospective, observational study of patients with schizophrenia designed to evaluate long-term treatment outcomes in routine clinical practice.MethodsParameters were assessed at baseline and at 3 month intervals for 2 years in patients initiated on risperidone long-acting injection (RLAI) (n = 1345) or a new oral antipsychotic (AP) (n = 277; 35.7% and 36.5% on risperidone and olanzapine, respectively) in Spain. Hospitalization prior to therapy was assessed by a retrospective chart review.ResultsAt 24 months, treatment retention (81.8% for RLAI versus 63.4% for oral APs, p < 0.0001) and reduction in Clinical Global Impression Severity scores (−1.14 for RLAI versus −0.94 for APs, p = 0.0165) were significantly higher with RLAI. Compared to the pre-switch period, RLAI patients had greater reductions in the number (reduction of 0.37 stays per patient versus 0.2, p < 0.05) and days (18.74 versus 13.02, p < 0.01) of hospitalizations at 24 months than oral AP patients.ConclusionsThis 2 year, prospective, observational study showed that, compared to oral antipsychotics, RLAI was associated with better treatment retention, greater improvement in clinical symptoms and functioning, and greater reduction in hospital stays and days in hospital in patients with schizophrenia. Improved treatment adherence, increased efficacy and reduced hospitalization with RLAI offer the opportunity of substantial therapeutic improvement in schizophrenia.

scholarly journals LONG-ACTING ANTIPSYCHOTICS AS A FACTOR FOR IMPROVING TREATMENT ADHERENCE IN SCHIZOPHRENIA: CASE REPORT

2014 ◽  
Vol Ano 4 ◽  
pp. 32-34
Author(s):  
VICTOR SICILIANO SOARES ◽  
CLAUDIANE SALLES DALTIO ◽  
CECÍLIA ATTUX
Keyword(s):  
Case Report ◽  
Treatment Adherence ◽  
Long Acting ◽  
Schizophrenia Case

Este artigo relata o caso de um paciente jovem em primeiro episódio psicótico e com dificuldade de adesão ao tratamento, no qual foi utilizado um antipsicótico de segunda geração de ação prolongada. Os antipsicóticos de longa ação devem ser considerados mais amplamente no tratamento da esquizofrenia pela facilidade do manejo e segurança na tomada da medicação, pois melhoram a adesão e, consequentemente, o prognóstico dos pacientes.

Psychiatrists’ opinion on treatment adherence in Delusional Disorder

2016 ◽  
Vol 33 (S1) ◽  
pp. S570-S570
Author(s):  
B. Girela Serrano ◽  
L. Aguado Bailón ◽  
P. Calvo ◽  
J.E. Muñoz Negro ◽  
J. Cervilla Ballesteros
Keyword(s):  
Treatment Adherence ◽  
Health Care Services ◽  
Delusional Disorder ◽  
Poor Adherence ◽  
Adherence To Treatment ◽  
Care Services ◽  
Active Compliance ◽  
Competing Interest ◽  
Long Acting ◽  
High Level

IntroductionDelusional Disorder (DD) F22 is a disease with low prevalence, probably underdiagnosed by clinical specialists due to the high level of functionality, low awareness of disease, low deterioration of patients and poor adherence to prescribed treatment. Adherence to treatment is considered to be one of the major difficulties that stand in the way of the treatment of DD. The present paper assessed psychiatrists’ opinion of the adherence to treatment of patients with DD.Material and methodsA self-administered survey was conducted on a sample of psychiatrists proceeding on a wide array of mental health care services. Participants provided their opinions regarding adherence to treatment. Descriptive statistics were subsequently calculated with SPSS.ResultsIn the opinion of our participants none of the patients have an active compliance of the treatment, 36% consider that the participation is partial or passive. It is also estimated that 57.5% reject the treatment but not totally and 6.5% believe that rejection is absolute.ConclusionsLiterature informs of the association of poor adherence to treatment and little or no improvement of patients, suggesting the need to address the lack of compliance and adherence to treatment as a crucial aspect to improve the prognosis of DD. To address this problem Long Acting Injections (LAIs) of Atypical Antipsychotics are postulated to be a plausible solution as a good treatment strategy. In order to improve the clinical practice in DD and obtain information for further effectiveness we emphasize the need of implementing clinical studies.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals PP029 Hospitalizations And Costs In Bipolar Disorder Patients Initiating Long-acting Injectable Antipsychotics

2017 ◽  
Vol 33 (S1) ◽  
pp. 83-83
Author(s):  
Mallik Greene ◽  
Tingjian Yan ◽  
Eunice Chang ◽  
Ann Hartry ◽  
Michael Broder
Keyword(s):  
Bipolar Disorder ◽  
Reference Group ◽  
Cohort Analysis ◽  
Linear Regression Models ◽  
Inpatient Hospitalization ◽  
Inpatient Hospitalizations ◽  
Long Acting ◽  
Bipolar Patients ◽  
The Impact

INTRODUCTION:Existing studies have not investigated the effectiveness of one long-acting injectable antipsychotic (LAI) versus another in preventing hospitalizations among patients with bipolar disorder (BD). This study was conducted to compare all-cause inpatient healthcare utilization and associated costs among BD patients who initiated LAIs.METHODS:This retrospective cohort analysis used the Truven Health Analytics MarketScan® Commercial and Medicaid claims database. Bipolar patients >18 years with at least one claim for one of the following LAIs were identified between 1 January 2013 and 30 June 2014 (identification period): aripiprazole, haloperidol, paliperidone, and risperidone. The first day of initiating an LAI was considered the index date. Logistic regression and generalized linear regression models were conducted to estimate risk of inpatient hospitalization and associated costs during the 1-year follow up.RESULTS:A total of 1,540 BD patients initiated an LAI: 14.5 percent aripiprazole, 16.3 percent risperidone, 21.0 percent haloperidol, and 48.1 percent paliperidone. With the aripiprazole cohort as the reference group, the odds of having any inpatient hospitalizations were significantly higher in haloperidol [Odds Ratio, OR (95 percent Confidence Interval, CI): 1.49 (1.01 - 2.19)] and risperidone [1.78 (1.19 - 2.66)] cohorts. The paliperidone cohort also had a higher risk of having a hospitalization than aripiprazole, but the difference was not statistically significant (p>.05). Among LAI initiators having any inpatient hospitalizations, the adjusted mean all-cause inpatient costs were lowest in the aripiprazole cohort (USD26,002), followed by risperidone (USD27,937), haloperidol (USD30,411), and paliperidone (USD33,240). However, the cost difference was not statistically significant.CONCLUSIONS:Our study findings highlight the value of aripiprazole in reducing all-cause inpatient hospitalizations and associated costs among patients with BD during the 1-year follow-up. It is worthwhile to note that bipolar diagnoses were identified from healthcare claims coded for reimbursement purposes, thus misclassification was possible. Future studies are warranted to understand the impact of LAI use in a longer period of time.

Strategies for optimizing medication adherence in schizophrenia

CNS Spectrums ◽  
2012 ◽  
Vol 17 (1) ◽  
pp. 31-41 ◽  
Author(s):  
Debbi A. Morrissette ◽  
Andrew J. Cutler
Keyword(s):  
Treatment Adherence ◽  
Cognitive Deficits ◽  
Treatment Team ◽  
Adverse Side Effects ◽  
Increased Risk ◽  
Medication Selection ◽  
Medication Efficacy ◽  
Dosing Strategy ◽  
Long Acting ◽  
Psychosocial Approaches

Medication nonadherence is a common problem in the treatment of schizophrenia. The consequences of nonadherence are numerous and can be quite serious, including increased risk of rehospitalization and suicide. There are numerous factors that affect a patient's decision and ability to take medication, including medication efficacy and tolerability, treatment regimen, cognitive deficits, and the patient's relationship with the treatment team. Fortunately, there are several strategies that may increase treatment adherence, including individualization of medication selection and dosing strategy to maximize efficacy and minimize adverse side effects, utilization of long-acting injectable depot formulations that eliminate the need for the patient to remember daily oral medication, and psychosocial approaches that emphasize the benefits of staying well.

Sign in / Sign up

Export Citation Format

Share Document